ischemic heart disease
Conditions
Interventions
interruption of prasugrel
interruption of clopidogrel
interruption of ticagrelor
Sponsors
Chiba University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are planned to interrupt a P2Y12 inhibitor
Exclusion criteria
Exclusion criteria: Patients who are adjudicated ineligible to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PRU change among P2Y12 inhibitors (prasugrel, clopidogrel, ticagrelor) | — |
Countries
Japan
Contacts
Public ContactTakanori Sato
Chiba University Graduate School of Medicine Department of cardiovascular medicine
Outcome results
None listed